Human Molecular Genetics, 2001, Vol. 10, No. 14 1519-1529
© 2001 Oxford University Press
Functional analysis of neurofibromatosis 2 (NF2) missense mutations
Department of Neurology, Washington University School of Medicine, Box 8111, 660 South Euclid Avenue, St Louis, MO 63110, USA
Neurofibromatosis 2 (NF2) is a tumor predisposition syndrome in which affected individuals develop nervous system tumors at an increased frequency. The most common tumor in individuals with NF2 is the schwannoma, which is composed of neoplastic Schwann cells lacking NF2 gene expression. Moreover, inactivation of the NF2 gene is observed in nearly all sporadic schwannomas, suggesting that the NF2 gene is a critical growth regulator for Schwann cells. In an effort to gain insights into the function of the NF2 gene product, merlin or schwannomin, we performed a detailed functional analysis of eight naturally occurring non-conservative missense mutations in the NF2 gene. Using a regulatable expression system in rat schwannoma cells, we analyzed proliferation, actin cytoskeleton-mediated events and merlin folding. In this report, we demonstrate that mutations clustered in the predicted
-helical region did not impair the function of merlin whereas those in either the N- or C-terminus of the protein rendered merlin inactive as a negative growth regulator. These results suggest that the key functional domains of merlin lie within the highly conserved FERM domain and the unique C-terminus of the protein.
+ To whom correspondence should be addressed. Tel: +1 314 362 7149; Fax: +1 314 362 2388; Email: gutmannd@neuro.wustl.edu
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M E Baser, L Kuramoto, R Woods, H Joe, J M Friedman, A J Wallace, R T Ramsden, S Olschwang, E Bijlsma, M Kalamarides, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2 J. Med. Genet., July 1, 2005; 42(7): 540 - 546. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-X. Sun, C. Haipek, D. R. Scoles, S. M. Pulst, M. Giovannini, M. Komada, and D. H. Gutmann Functional analysis of the relationship between the neurofibromatosis 2 tumor suppressor and its binding partner, hepatocyte growth factor-regulated tyrosine kinase substrate Hum. Mol. Genet., December 1, 2002; 11(25): 3167 - 3178. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimizu, A. Seto, N. Maita, K. Hamada, S. Tsukita, S. Tsukita, and T. Hakoshima Structural Basis for Neurofibromatosis Type 2. CRYSTAL STRUCTURE OF THE MERLIN FERM DOMAIN J. Biol. Chem., March 15, 2002; 277(12): 10332 - 10336. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Bashour, J.-J. Meng, W. Ip, M. MacCollin, and N. Ratner The Neurofibromatosis Type 2 Gene Product, merlin, Reverses the F-Actin Cytoskeletal Defects in Primary Human Schwannoma Cells Mol. Cell. Biol., February 15, 2002; 22(4): 1150 - 1157. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-X. Sun, V. A. Robb, and D. H. Gutmann Protein 4.1 tumor suppressors: getting a FERM grip on growth regulation J. Cell Sci., January 11, 2002; 115(21): 3991 - 4000. [Abstract] [Full Text] [PDF] |
||||




